Company intelligence / Profile preview

HAL Allergy Group

Leiden, Netherlands

Ownership: Private
Employees: ~281
Development stage: Commercial

Overview

HAL Allergy has successfully completed Phase III trials for its sublingual birch pollen allergen product and First-In-Human studies for a subcutaneous peanut allergy therapy. It markets established SCIT and SLIT products widely in Europe.

Therapeutic areas: Immunology
Modalities: Allergen immunotherapies including subcutaneous immunotherapy (SCIT)Sublingual immunotherapy (SLIT)Biopharmaceutical products for allergy treatment and diagnostics
Industry: Biotech

Drug pipeline

17 assets

Purethal

16 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on HAL Allergy Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAL Allergy Group.

Explore the full profile